Literature DB >> 18831970

A therapeutic dose of zolpidem has limited abuse-like effects in drug-naïve females: a pilot study.

Stephanie C Licata1, David M Penetar, Steven Dunlap, Scott E Lukas.   

Abstract

Zolpidem has abuse potential, particularly among individuals with histories of drug abuse. This double-blind, placebo-controlled, cross over pilot study investigated the subjective effects of zolpidem (10 mg) in drug-naïve females. Over the course of a 5-h period vital signs were monitored and a series of computerized questionnaires was administered. Results indicate that zolpidem engendered subjective effects characteristic of hypnotic drugs, but reduced ratings of drug liking, willing to take again, and willing to pay for, relative to placebo. Thus, a therapeutic dose of zolpidem may have limited potential for misuse among females who have no experience with drugs of abuse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18831970      PMCID: PMC2585358          DOI: 10.1016/j.ejphar.2008.09.011

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

1.  Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

Authors:  S M Troy; I Lucki; M A Unruh; W H Cevallos; C A Leister; P T Martin; P M Furlan; R Mangano
Journal:  J Clin Psychopharmacol       Date:  2000-06       Impact factor: 3.153

2.  Assessing pentobarbital preference in normal volunteers using a cumulative dosing procedure.

Authors:  H de Wit; J Pierri; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Reinforcing properties of lorazepam in normal volunteers.

Authors:  H de Wit; C E Johanson; E H Uhlenhuth
Journal:  Drug Alcohol Depend       Date:  1984-01       Impact factor: 4.492

4.  Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans.

Authors:  C R Rush; R W Baker; K Wright
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

5.  Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans.

Authors:  C R Rush; S Madakasira; N H Goldman; W L Woolverton; J K Rowlett
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

Review 6.  Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse.

Authors:  R R Griffiths; E M Weerts
Journal:  Psychopharmacology (Berl)       Date:  1997-11       Impact factor: 4.530

7.  Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates.

Authors:  James K Rowlett; Donna M Platt; Snjezana Lelas; John R Atack; Gerard R Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

8.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

Authors:  D J Greenblatt; J S Harmatz; L L von Moltke; B L Ehrenberg; L Harrel; K Corbett; M Counihan; J A Graf; M Darwish; P Mertzanis; P T Martin; W H Cevallos; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1998-11       Impact factor: 6.875

9.  The abuse potential of zolpidem administered alone and with alcohol.

Authors:  C J Wilkinson
Journal:  Pharmacol Biochem Behav       Date:  1998-05       Impact factor: 3.533

10.  A postmarketing study of relative abuse liability of hypnotic sedative drugs.

Authors:  Jerome H Jaffe; Roger Bloor; Ilana Crome; Malcolm Carr; Farrukh Alam; Arnol Simmons; Roger E Meyer
Journal:  Addiction       Date:  2004-02       Impact factor: 6.526

View more
  8 in total

Review 1.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

2.  Zolpidem reduces the blood oxygen level-dependent signal during visual system stimulation.

Authors:  Stephanie C Licata; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-05-30       Impact factor: 5.067

3.  Zolpidem does not serve as reinforcer in humans subjected to simulated shift work.

Authors:  Matthew G Kirkpatrick; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin; Carl L Hart
Journal:  Drug Alcohol Depend       Date:  2010-07-23       Impact factor: 4.492

4.  Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward.

Authors:  Lauren M Reynolds; Elif Engin; Gabriella Tantillo; Hew Mun Lau; John W Muschamp; William A Carlezon; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

5.  Modest abuse-related subjective effects of zolpidem in drug-naive volunteers.

Authors:  Stephanie C Licata; Yasmin Mashhoon; Robert R Maclean; Scott E Lukas
Journal:  Behav Pharmacol       Date:  2011-04       Impact factor: 2.293

6.  A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 T.

Authors:  Stephanie C Licata; J Eric Jensen; David M Penetar; Andrew P Prescot; Scott E Lukas; Perry F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2009-01-06       Impact factor: 4.530

7.  'Z-trip'? A Comprehensive Overview and a Case-series of Zolpidem Misuse.

Authors:  Laura Orsolini; Stefania Chiappini; Paolo Grandinetti; Angelo Bruschi; Roberta Testa; Alessandra Provenzano; Domenico De Berardis; Umberto Volpe
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

8.  Eszopiclone for insomnia.

Authors:  Susanne Rösner; Christian Englbrecht; Renate Wehrle; Göran Hajak; Michael Soyka
Journal:  Cochrane Database Syst Rev       Date:  2018-10-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.